Date: 2017-06-01
Type of information: Construction of a production plant
Compound: new production facility at Grange Castle site
Company: Takeda Pharmaceutical (Japan)
Therapeutic area:
Type agreement: construction of a production plant
Action mechanism:
Disease:
Details:
- • On June 1, 2017, Takeda Pharmaceutical announced that a groundbreaking ceremony had been held for its new
production facility at the existing Grange Castle site in Ireland.
Takeda’s existing footprint at the Grange Castle site will be expanded with the construction of a new standalone, high-containment production facility dedicated to manufacturing its
oncology product Ninlaro® for global markets. The investment will create approximately 40 new jobs over the next two years. The construction of the plant, which begins in June 2017, will be managed by Project Management Group with over 40 million euros investment in total. The plant is scheduled to be completed in Q2 FY2018 and become operational to commence shipment of secondary packaged product in the second half of FY2018.
The new production facility will be unique in that it will house the Drug Substance, Drug Product, Primary and Secondary Packaging and QC processes all under one roof.
Ninlaro® was approved in November 2015 by the FDA. It is the
first and only once-weekly oral proteasome inhibitor launched in the U.S. for the treatment of patients with multiple myeloma who have received at least one prior therapy, enabling an all-oral proteasome inhibitor-based triplet treatment regimen for the first time. It was approved by the Japanese Ministry of Health, Labour and Welfare in March 2017 and launched in May as the first oral
proteasome inhibitor in Japan, indicated in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma. Ninlaro® has also been approved by the European Commission.
- • On December 5, 2016, Minister for Jobs, Enterprise and Innovation Mary Mitchell O’Connor announced that Takeda Pharmaceutical is to invest €40m in a new facility at their Grange Castle site in Dublin. The investment will expand the site’s existing footprint, with the construction of a new standalone high containment production facility dedicated to manufacturing Ninlaro® for global markets. The investment will create approximately 40 new jobs. This investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland. Takeda first set up operations in Ireland in 1997 manufacturing products for global markets. In 2002 Takeda chose Dublin as the location for its first active pharmaceutical ingredient (API) facility outside of Japan.
Financial terms:
Latest news:
Is general: Yes
